SkinHealth Systems Inc 8-K, filed Jun 21, 2023
SkinHealth Systems Inc. (SKIN)
8-K
2023-06-21
For: 2023-06-14
View Original
Added on
April 10, 2026
About this 8-K
SkinHealth Systems Inc filed this 8-K on June 21, 2023, reporting on events of June 14, 2023.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2023
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices)
(Zip Code)
(800 ) 603-4996
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
The | ||||||||||||||
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders
On June 14, 2023, The Beauty Health Company (the “Company”) held its 2023 annual meeting of stockholders (the “Annual Meeting”) in a virtual format. At the close of business on April 17, 2023, the record date for the Annual Meeting (the “Record Date”), there were 132,628,714 shares of the Company’s Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”) issued and outstanding, which constituted all of the issued and outstanding capital stock of the Company as of the Record Date. At the Annual Meeting, 121,899,846 of the Company’s 132,628,714 outstanding shares of Class A Common Stock entitled to vote as of the Record Date, or approximately 91.91%, were represented by proxy or in person (virtually), and, therefore, a quorum was present.
The proposals voted on at the Annual Meeting are more fully described in the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 28, 2023 (the “Proxy Statement”).
The final voting results on the proposals presented for stockholder approval at the Annual Meeting are as follows:
Proposal No. 1: Election of Class II Directors
The Company’s stockholders re-elected each of the three Class II directors listed below, each to hold office for a period of three years until the Company’s 2026 annual meeting of stockholders, or until his successor is duly appointed or elected and qualified, subject to prior death, resignation, or removal, as follows:
| Nominees | Votes For | Votes Withheld | Broker Non-Votes | |||||||||||||||||
| Michael D. Capellas | 82,219,150 | 31,684,554 | 7,996,142 | |||||||||||||||||
| Dr. Julius Few | 91,102,606 | 22,801,098 | 7,996,142 | |||||||||||||||||
| Brian Miller | 90,921,951 | 22,981,753 | 7,996,142 | |||||||||||||||||
Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent, registered public accounting firm for the fiscal year ending December 31, 2023, as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 121,409,900 | 485,100 | 4,846 | 0 | ||||||||
Proposal No. 3: Advisory Vote on the Compensation of the Named Executive Officers
The Company’s stockholders approved, on an advisory, non-binding basis, the compensation paid by the Company to its named executive officers as disclosed in the Proxy Statement, as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 113,454,143 | 425,849 | 23,712 | 7,996,142 | ||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 21, 2023 | The Beauty Health Company | |||||||
| By: | /s/ Liyuan Woo | |||||||
| Name: | Liyuan Woo | |||||||
| Title: | Chief Financial Officer | |||||||